MONTRÉAL, January 27, 2023 – RejuvenRx Inc., an emerging biotechnology company developing novel small molecules-based targeted therapies focusing on stem cell biology, announced today a strategic investment from IRICoR, one of its co-founders.
IRICoR, a Centre of Excellence in Commercialization and Research with a focus on drug discovery, co-founded RejuvenRx alongside ExCellThera and its shareholders. This new financial investment in RejuvenRx will help support the company’s growing oncology and aging programs.
“We believe this strategic investment by IRICoR marks the beginning of a new chapter of growth for RejuvenRx and reaffirms both the relevance of our scientific approach and our strategic position within this rapidly evolving industry” said Dr. Anne Marinier, President & CEO of RejuvenRx.
“We are very confident at IRICoR that our investment in RejuvenRx will contribute to strategically position the company as a successful early-stage biotech in drug discovery. With IRICoR’s early support, RejuvenRx already has winning ingredients, including promising oncology and aging programs in areas of clear and growing unmet needs, advanced series of molecules and novel targets, and a seasoned management team” concluded Dr. Nadine Beauger, President & CEO of IRICoR.
About RejuvenRx
RejuvenRx is a biotechnology company working on delivering precision therapies to overcome cancer and aging. RejuvenRx is developing its main asset, a series of small molecules promoting tissue regenerative capacity aimed at treating cancers, aging frailty and other diseases. Its growing pipeline is propelled by an oncology target identification platform, and access to highly diversified libraries of small molecules and solid drug optimization expertise. www.rejuvenrx.com
About IRICoR
Designated as a Centre of Excellence in Research and Commercialization by the Canadian government and based at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, IRICoR is a pan-Canadian leader in the de-risking of early-stage assets in the field of drug discovery. IRICoR’s mandate is to accelerate the discovery, development, and commercialization of novel therapies in cancer and rare diseases, through strategic licenses with industry and new company creation.